Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
ARS Pharmaceuticals, Inc. (SPRY) is a biopharmaceutical innovator developing neffy®, a needle-free epinephrine nasal spray for emergency treatment of severe allergic reactions. This page provides investors and healthcare stakeholders with timely, verified updates on the company’s progress in redefining allergy care through intranasal technology.
Discover comprehensive coverage of SPRY’s regulatory milestones, clinical trial results, and strategic partnerships. Our news collection focuses on developments impacting neffy’s market adoption, manufacturing updates, and scientific validation of its needle-free delivery system. Key updates include FDA communications, international expansion efforts, and patient access initiatives.
This resource serves as your central hub for understanding SPRY’s role in addressing critical gaps in anaphylaxis treatment. Bookmark this page for ongoing insights into how ARS Pharmaceuticals combines biopharmaceutical innovation with patient-centric solutions in emergency care.
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced that the FDA has scheduled an Advisory Committee meeting on May 11, 2023, to review the NDA for neffy, a potential first non-injectable epinephrine nasal spray for allergic reactions, including anaphylaxis. The FDA deemed the Advisory Committee meeting important due to the new delivery method and the complexities of clinical efficacy trials. CEO Richard Lowenthal expressed optimism about the meeting as a positive step towards neffy's potential approval. The PDUFA target action date for neffy is set for mid-2023.
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) provided an update on its progress regarding neffy®, a needle-free nasal spray for treating severe allergic reactions. The FDA and EMA are currently reviewing their New Drug Application and Marketing Authorization Application, with a PDUFA target action date expected in mid-2023. Financially, ARS reported a robust cash position of $274.4 million, sufficient to support operations for the next three years. R&D expenses for Q4 2022 were $4.7 million, leading to a net loss of $14.4 million for the quarter and $34.7 million for the year. The company is well-prepared for a potential U.S. launch if approved.
FAQ
What is the current stock price of ARS Pharms (SPRY)?
What is the market cap of ARS Pharms (SPRY)?
